On November 16, 2020, Hacarus Inc. closed the transaction. The company received its second tranche. The transaction included participation from new investors Japan Finance Corporation, PARKINSON Laboratories Co., Ltd., Resona Capital Investment Limited Partnership Fund No. 6 a fund managed by Resona Capital Co., Ltd. and MTG Ventures Co., Ltd. along with returning investors Ohara Pharmaceutical Co., Ltd., Miyako Capital Co., Ltd. and The Bank of Kyoto, Ltd. (TSE:8369). The company has received ¥1.3 Billion in funding till date.